

# TABLE OF CONTENTS

Preface .....	iii
Disclosure of Potential Conflicts of Interest .....	iv
Continuing Pharmacy Education and Recertification Instructions .....	v

Chronic Illnesses I .....	1
Faculty Panel .....	3

## ANTIRHEUMATIC DRUGS

By Rachel A. Burke, Pharm.D., BCACP; and  
Nicole D. White, Pharm.D.

Learning Objectives .....	9
Introduction .....	9
Epidemiology .....	9
Baseline Knowledge Statements .....	9
Additional Readings .....	9
Nonbiologic DMARDs .....	10
Biologic DMARDs .....	10
RA Treatment .....	15
Safety Considerations of Biologic DMARDs .....	18
Biologic DMARDs in High-Risk Patients .....	20
Patient Education .....	23
References .....	24
Self-Assessment Questions .....	29

## OSTEOARTHRITIS

By Jennifer N. Clements, Pharm.D., BCPS, BCACP, CDE

Learning Objectives .....	33
Introduction .....	33
Baseline Knowledge Statements .....	33
Additional Readings .....	33
Etiology .....	34
Pathophysiology .....	34
Clinical Features .....	34
Treatment Guidelines .....	37
Other Issues .....	48
References .....	49
Self-Assessment Questions .....	53

## OVERWEIGHT AND OBESITY

By Kaelen C. Dunican, Pharm.D.; and Courtney Jarvis, Pharm.D.

Learning Objectives .....	57
Introduction .....	57
Baseline Knowledge Statements .....	57
Additional Readings .....	57
Pathophysiology .....	58
Treatment .....	62
References .....	74
Self-Assessment Questions .....	76

## TRANSITIONS OF CARE

By Sheryl J. Herner, Pharm.D., BCPS, CPPS; and Valerie S. Ganetsky,  
Pharm.D., BCPS

Learning Objectives .....	79
Introduction .....	79
Baseline Knowledge Statements .....	79
Additional Readings .....	79
Defining TOC .....	80
TOC Interventions and Outcomes in Primary Literature .....	84
Established TOC Models .....	84
National Initiatives and Resources .....	89
Performance Metrics .....	91
Reimbursement .....	93
References .....	94
Self-Assessment Questions .....	97

Chronic Illnesses II .....	101
Faculty Panel .....	103

## MYELODYSPLASTIC SYNDROMES

By Kristen B. McCullough, Pharm.D., BCPS, BCOP; and Julianna  
Merten, Pharm.D., BCPS, BCOP

Learning Objectives .....	109
Introduction .....	109
Baseline Knowledge Statements .....	109
Additional Readings .....	109
Pathophysiology .....	111
Clinical Presentation and Diagnosis .....	113
Prognosis .....	113
Treatment .....	113
Emerging Therapies .....	123
Treatment approach .....	123
<b>References .....</b>	<b>124</b>
Self-Assessment Questions .....	128

## CHRONIC MYELOID LEUKEMIA

By Marc A. Earl, Pharm.D., BCOP

Learning Objectives .....	131
Introduction .....	131
Baseline Knowledge Statements .....	131
Additional Readings .....	131
Presentation and Diagnosis .....	132
Treatment Response Goals and Criteria .....	133
Resistance or Intolerance to Initial Therapy .....	135
Hematopoietic Stem Cell Transplantation .....	136
Monitoring .....	136
References .....	139
Self-Assessment Questions .....	141

## PHARMACOLOGY OF NEW TARGETED THERAPIES

By Salvatore M. Bottiglieri, Pharm.D., BCOP

Learning Objectives .....	145
Introduction .....	145

Baseline Knowledge Statements .....	145
Additional Readings .....	145
Pharmacology of Targeted Therapies .....	147
Therapeutics of Targeted Therapy .....	150
References .....	163
Self-Assessment Questions .....	165

## ORAL CHEMOTHERAPY

*By Margaret M. Charpentier, Pharm.D., BCPS; and Karen R. Smethers, Pharm.D., BCOP*

Learning Objectives .....	169
Introduction .....	169
Baseline Knowledge Statements .....	169
Additional Readings .....	169
Monitoring .....	178
References .....	189
Self-Assessment Questions .....	191

Chronic Illnesses III .....	195
Faculty Panel .....	197

## MANAGEMENT OF PATIENTS ON DIALYSIS

*By Neeta Bahal O'Mara, Pharm.D., BCPS*

Learning Objectives .....	203
Introduction .....	203
Baseline Knowledge Statements .....	203
Additional Readings .....	203
Anemia .....	204
Mineral and Bone Disorder .....	214
References .....	222
Self-Assessment Questions .....	224

## LONG-TERM MANAGEMENT AFTER KIDNEY TRANSPLANTATION

*By Steven Gabardi, Pharm.D., FCCP, BCPS; and Christin Rogers, Pharm.D., FCCP, BCPS*

Learning Objectives .....	229
Introduction .....	229
Baseline Knowledge Statements .....	229
Additional Readings .....	229
Induction Therapy .....	230
Maintenance Immunosuppression .....	230
Drug-Drug Interactions .....	237
Immunologic Complications .....	238
Long-term Management Issues .....	242
Pharmacist and Patient Education Points .....	251
References .....	252
Self-Assessment Questions .....	256

## BIOLOGIC THERAPIES FOR GASTROINTESTINAL DISEASES

*By Rima A. Mohammad, Pharm.D., BCPS; and Michael A. Smith, Pharm.D., BCPS*

Learning Objectives .....	261
Introduction .....	261
Baseline Knowledge Statements .....	261
Additional Readings .....	261
Anti-TNF- $\alpha$ Agents .....	263
Interleukin Antagonists .....	277
Cluster of Differentiation .....	277
Janus Kinase Inhibitors .....	279
Integrin Inhibitors .....	280
Interferon- $\gamma$ Inhibitor .....	281
Early Clinical Trials .....	281
References .....	282
Self-Assessment Questions .....	287